Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate Efficacy and Safety of Ropanicant in Patients With Major Depressive Disorder

NCT06836063 is registered in ClinicalTrials.gov with Suven Life Sciences Limited as lead sponsor.

NCT NCT06836063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06836063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate Efficacy and Safety of Ropanicant in Patients With Major Depressive Disorder
Lead sponsor
Suven Life Sciences Limited
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2025
Completion date
February 23, 2026
Enrollment
214 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)